The effect of Fel d 1‐derived T‐cell peptides on upper and lower airway outcome measurements in cat‐allergic subjects
- 31 August 2005
- Vol. 60 (10), 1269-1274
- https://doi.org/10.1111/j.1398-9995.2005.00885.x
Abstract
We previously showed that overlapping Fel d 1-derived T-cell peptides inhibited surrogate markers of allergy (i.e. early and late-phase skin reactions and T-cell function) in cat allergic subjects. The present pilot study was designed to determine whether this treatment affected clinically relevant outcome measurements such as the allergen-induced nasal and bronchial reactions, and asthma/rhinitis quality of life (QOL). Sixteen cat-allergic asthmatic subjects who gave a dual (early and late) asthmatic response (DAR) to inhaled cat allergen were randomly assigned to receive either Fel d 1 peptides (approximately 300 mug in increasing, divided doses) or placebo (8 active : 8 placebo). Twelve single early responders (SER) were also studied in an open fashion design. Allergen-induced bronchial and nasal measurements as well as the QOL was measured at baseline, 4-8 weeks (follow-up 1 (FU1)) and 3-4 months (FU2). In the active, but not placebo, group there were significant decreases in the late asthmatic reaction (LAR) to whole cat dander (P = 0.03) at FU2 but with no between group difference. There were also significant improvements in asthma quality of life (QOL) scores [asthma-activity limitation (P = 0.014); rhinitis-sleep (P = 0.024), non-nose/non-eye symptoms (P = 0.031), nasal problems (P = 0.015)]. In the open study Fel d 1 peptide treatment resulted in significant decreases in number of sneezes (P = 0.05), weight of nasal secretions (P = 0.04) and nasal blockage (P = 0.01) following allergen challenge. Multiple, short, overlapping Fel d 1 T-cell peptides have potential for inhibiting upper and lower airway outcome measurements in cat allergic patients. Larger, dose-ranging, studies are required before firm conclusions on clinical efficacy of peptide allergen therapy can be made.Keywords
This publication has 11 references indexed in Scilit:
- Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double‐blind placebo‐controlled studyAllergy, 2004
- In Vivo Instruction of Suppressor Commitment in Naive T CellsThe Journal of Experimental Medicine, 2004
- Allergen-based peptide immunotherapy is associated with functional modifications in allergen-specific T-cell subpopulations*1Journal of Allergy and Clinical Immunology, 2004
- Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trialThe Lancet, 2002
- Allergen-Derived T Cell Peptide-Induced Late Asthmatic Reactions Precede the Induction of Antigen-Specific Hyporesponsiveness in Atopic Allergic Asthmatic SubjectsThe Journal of Immunology, 2001
- Attenuation of the Allergen-induced Late Asthmatic Reaction by Cyclosporin A Is Associated with Inhibition of Bronchial Eosinophils, Interleukin-5, Granulocyte Macrophage Colony-Stimulating Factor, and EotaxinAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Validation of the standardized version of the Rhinoconjunctivitis Quality of Life QuestionnaireJournal of Allergy and Clinical Immunology, 1999
- Validation of a Standardized Version of the Asthma Quality of Life QuestionnaireSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1999
- Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to catsJournal of Allergy and Clinical Immunology, 1998
- Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venomJournal of Allergy and Clinical Immunology, 1998